A Nanobody–Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy
Journal of Medicinal Chemistry · 14.09.2023 · 66 (17) · 11951-11964
DOI: 10.1021/acs.jmedchem.3c00557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.08.2023. Verfasst von Zhennan Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, IGCME, Sun Yat-sen University, Guangzhou 510275, China. Hauptthemen laut MEDLINE: Prodrugs. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Guangzhou Municipal Science and Technology Project, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Checkpoint inhibitors have been used with chemotherapy to improve antitumor efficacy. However, overcoming the immunosuppressive effect of chemotherapeutics remains a challenge. We report a nanobody-catalyst conjugate Ru-PD-L1 by fusing a ruthenium catalyst to an anti-PD-L1 nanobody. After administration of Ru-PD-L1 and a doxorubicin (DOX) prodrug, Ru-PD-L1 disrupts the PD-L1/PD-1 interaction and catalyzes the uncaging of the DOX prodrug. The spatially confined release of DOX reduces its systemic toxicity and leads to immunogenic cell death (ICD). The induced ICD triggers antitumor immune responses, which are further amplified by PD-L1 blockade to elicit synergistic chemo-immunotherapy, substantially increasing the number of tumor-infiltrating T-cells by 49.7% compared with the controls, thereby exhibiting high antitumor activity and low cytotoxicity in murine models. The combinational treatment could inhibit the growth of mice tumors by 67.7% compared to the control group. This combinational approach circumvents the negative immunogenic effects of chemotherapeutics and provides a potential chemo-immunotherapy strategy for human cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, IGCME, Sun Yat-sen University, Guangzhou 510275, China.
- Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
- Guangdong Engineering & Technology Research Center for Disease-Model Animals, Laboratory Animal Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
- Key Laboratory of Tropical Disease Control of the Ministry of Education, Sun Yat-sen University, Guangzhou 510080, China.
- Center for Precision Medicine, Sun Yat-sen University, Guangzhou 510080, China.
ORCID-Profile: Wei Xia, Zong-Wan Mao
Förderung
- National Key Research and Development Program of China
- Guangzhou Municipal Science and Technology Project
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Zhao, Z., Wang, X., Wang, J., Li, Y., Lin, W., Lu, K., Chen, J., Xia, W., & Mao, Z. W. (2023). A Nanobody–Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy. Journal of Medicinal Chemistry, 66(17), 11951-11964. https://doi.org/10.1021/acs.jmedchem.3c00557
Vancouver
Zhao Z, Wang X, Wang J, Li Y, Lin W, Lu K, et al. A Nanobody–Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy. Journal of Medicinal Chemistry. 2023;66(17):11951-11964. doi:10.1021/acs.jmedchem.3c00557
BibTeX
@article{Zhao2023,
author = {Zhao, Zhennan and Wang, Xinyu and Wang, Jinhui and Li, Yiyi and Lin, Wenkai and Lu, Kai and Chen, Jun and Xia, Wei and Mao, Zong-Wan},
title = {A Nanobody–Bioorthogonal Catalyst Conjugate Triggers Spatially Confined Prodrug Activation for Combinational Chemo-immunotherapy},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {17},
pages = {11951--11964},
doi = {10.1021/acs.jmedchem.3c00557}
}
EUVIMED